Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218597 | 0.90 | AR (0.66) | ARPGRHDAC1 | |
| SCHEMBL7785957 | 0.90 | AR (0.66) | ARPGR | |
| SCHEMBL2217609 | 0.90 | AR (0.61) | ARPGR | |
| SCHEMBL16845631 | 0.89 | AR (0.65) | ARPGRHDAC3HDAC4HDAC1 | |
| SCHEMBL26451505 | 0.89 | AR (0.65) | ARPGRHDAC1 | |
| SCHEMBL4028958 | 0.89 | AR (0.67) | ARPGR | |
| SCHEMBL12482345 | 0.87 | AR (0.63) | ARPGRHDAC3HDAC4HDAC1 | |
| SCHEMBL7779087 | 0.87 | PGR (0.66) | ARPGR | |
| SCHEMBL3667680 | 0.87 | PGR (0.65) | ARPGR | |
| SCHEMBL2218381 | 0.87 | PGR (0.65) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2242745-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009097995-A1 | NOVEL PHENYL-SUBSTITUTED IMIDAZOLIDINES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178134-A1 | Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof | FABP4, GPR119, PGC | AR 3140/4885PGR 1833/4885HDAC3 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.